Poolbeg Pharma secures South African patent for lead drug candidate
Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish
European patent boosts Poolbeg Pharma's POLB 001 IP portfolio
Poolbeg Pharma has begun an exciting new clinical trial - ICYMI
Poolbeg Pharma shows clinical progress with latest updates
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Poolbeg Pharma gets positive FDA feedback for development pathway of lead cancer therapy asset
Poolbeg Pharma secures Canadian patent for cancer immunotherapy drug POLB 001
Poolbeg Pharma PLC (POLBF) Q4 2025 Earnings Call Transcript
Poolbeg eyes transformative summer with POLB 001 data in prospect
FTSE 100 Live: BP and Shell provide boost as oil hits $110, Barclays falls on results
Poolbeg Pharma eyes partnering deals as cancer immunotherapy trial heads for summer data
FTSE 100 Live: London blue-chips led lower by miners, builders and airlines
Poolbeg Pharma advances POLB 001 into UK trial - ICYMI
Poolbeg Pharma advances POLB 001 into UK trial - ICYMI
Cavendish sees Poolbeg MHRA clearance as key de-risking event with 313% upside to target
Cavendish sees Poolbeg MHRA clearance as key de-risking event with 313% upside to target
FTSE 100 Live: Shares mixed as Iran talks awaited, with Barratt, Standard Life and Rank leading
Poolbeg Pharma wins UK regulatory clearance for cancer immunotherapy trial
Poolbeg Pharma wins UK regulatory clearance for cancer immunotherapy trial
Twilio upgraded, price target boosted on voice AI growth potential
Accesso, Light Science Technologies, Poolbeg Pharma, Digitalbox, RC Fornax, Gaming Realms
Poolbeg Pharma on patent grant and plans - ICYMI
Poolbeg Pharma on patent grant and plans - ICYMI
Poolbeg Pharma shares rise 10% as Australian patent grant bolsters POLB 001 commercial appeal
Poolbeg Pharma shares rise 10% as Australian patent grant bolsters POLB 001 commercial appeal
Poolbeg Pharma secures first national patent for cancer immunotherapy side-effect treatment
Oracle outlook seen as ‘first step’ in countering AI disruption fears: Wedbush
Bumble shares jump on revenue beat, stabilizing user trends
Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board
Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board
Poolbeg Pharma boosted as peer-reviewed Immunology paper marks 'important milestone'
Poolbeg Pharma boosted as peer-reviewed Immunology paper marks 'important milestone'
Poolbeg Pharma eyes 2026 milestones after year of achievements
Poolbeg Pharma eyes 2026 milestones after year of achievements
Dow Jones leads Wall Street lower, Paramount gatecrashes Netflix-Warner deal
Lululemon faces margins, sales headwinds in Q3 as brand momentum erodes: Jefferies
NICE downgraded by Wedbush on mounting AI competition, margin pressures
Cavendish sees Poolbeg's POLB 001 gaining strategic importance as CRS research expands
Cavendish sees Poolbeg’s POLB 001 gaining strategic importance as CRS research expands
Poolbeg's POLB 001 trial chosen for major cancer-immunotherapy safety initiative
Poolbeg’s POLB 001 trial chosen for major cancer-immunotherapy safety initiative
Poolbeg jumps 9% on new European patent for inflammation-targeting drug
Poolbeg jumps 9% on new European patent for inflammation-targeting drug
Poolbeg lands European patent for experimental flu treatment
Poolbeg Pharma CEO on POLB001 & GLP-1 trial plans - ICYMI
Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript
Poolbeg shares up 3% as drug developer eyes busy period
Poolbeg Pharma hails progress in first half of the year